FDA OKs New Abbott HCV Test

[Guest guest]

http://www.hivandhepatitis.com/hep_c/news/2011/0524_2011_b.html

FDA OKs New Abbott HCV Test

SUMMARY

Abbott last week announced that the FDA approved a new PCR blood test for

hepatitis C virus (HCV) with a 12 IU/mL limit of detection and quantification.

Below is an edited excerpt from a recent Abbott press release describing the new

assay.

Abbott Receives FDA Approval for Molecular

Test for Hepatitis C

Abbott Park, Illinois -- May 18, 2011 -- Abbott (NYSE: ABT) announced today that

it has received approval from the U.S. Food and Drug Administration to market

its RealTime PCR (polymerase chain reaction) test for measuring the viral load

of hepatitis C (HCV), the leading cause of liver cancer in the United States.

The Abbott RealTime HCV assay, developed for use on the Abbott m2000 system, is

intended for use as an aid in the management of HCV-infected patients undergoing

antiviral therapy. The assay measures HCV RNA levels at baseline and during

treatment and can be utilized to predict sustained and non-sustained virological

response to HCV therapy. The results from the RealTime HCV assay must be

interpreted within the context of all relevant clinical and laboratory findings.

The Abbott RealTime HCV assay is not for screening blood, plasma, serum or

tissue donors for HCV, or to be used as a diagnostic test to confirm the

presence of HCV infection.

" With the addition of the HCV assay to its automated m2000 system, Abbott is the

only molecular diagnostics supplier in the U.S., to offer viral load assays for

HIV, HBV and HCV, and a combination test for chlamydia and gonorrhea, on a

single molecular platform, " said ph s, MD, associate medical director,

Abbott Molecular. " This enables laboratories to consolidate sexually transmitted

and infectious disease testing to improve workflow and productivity. Also,

having a single manufacturer of these tests provides the clinician with a level

of assurance of consistency and quality when managing patients. "

The Abbott RealTime HCV test offers precise measurement (quantitation) of HCV in

human plasma or serum. It is a highly sensitive HCV viral load test and the only

one for which the limit of detection (lowest level of virus that generates a

positive result) and the limit of quantitation (lowest exact viral load

measurement) are the same, 12 IU/mL. This level of sensitivity enables

clinicians to measure very low levels of the HCV virus to gauge success of

antiviral drug treatment for eradicating the infection.

" Monitoring HCV RNA levels is important in the management of the disease with

antiviral medications such as interferon and ribavirin, " said , MD, a

gastroenterologist and hepatitis researcher with the Schiff Liver Institute and

Center for Liver Diseases in Miami, and clinical investigator and consultant for

Abbott. " Viral load measurements help physicians determine whether to begin

antiviral therapy, influence decisions on dosing and therapy duration, and

identify drug resistant strains. "

" The Abbott RealTime HCV assay detects and measures the six most common HCV

genotypes by targeting an essential, highly conserved segment of the viral

genome, " said Stafford O', head of Abbott's molecular diagnostics business.

" It is a highly sensitive molecular assay and offers complete coverage of all

HCV genotypes, as demonstrated in peer reviewed publications. "

A study published in the June 2009 edition of the Journal of Clinical

Microbiology (Chevaliez, Bouvier-Alias, and Pawlotski) concluded that " the

Abbott m2000 RealTime PCR system for HCV RNA quantification is sensitive,

specific, and precise; that the results are reproducible; and that the

platform's broad dynamic range of quantification is well suited to HCV RNA

monitoring in the clinical setting. "

In addition to its HCV in vitro diagnostic products, Abbott currently has four

investigational pharmaceutical compounds in phase 2 clinical trials for the

treatment of HCV, including a protease inhibitor, two polymerase inhibitors and

an NS5A inhibitor.

About the Abbott m2000 System

Abbott's automated molecular diagnostics system, the m2000, utilizes real-time

polymerase chain reaction (PCR) technology for detecting and monitoring

infectious diseases and is designed to provide clinical laboratories a unique

system that fully automates all of the complex and heavily manual steps often

associated with molecular diagnostics.

Abbott currently markets the m2000 system and a menu of infectious disease

assays in countries throughout the world.

About Abbott Molecular

Abbott Molecular, abbottmolecular.com, is a leader in molecular diagnostics --

the analysis of DNA, RNA, and proteins at the molecular level. Abbott

Molecular's tests can also detect subtle but key changes in patients' genes and

chromosomes and have the potential for earlier detection or diagnosis, can

influence the selection of appropriate therapies, and may improve monitoring of

disease progression.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the

discovery, development, manufacture and marketing of pharmaceuticals and medical

products, including nutritionals, devices, and diagnostics. The company employs

nearly 90,000 people and markets its products in more than 130 countries.

5/24/11

Source

Abbott. Abbott Receives FDA Approval for Molecular Test for Hepatitis C. Press

release. May 18, 2011.

[Guest guest]

http://www.hivandhepatitis.com/hep_c/news/2011/0524_2011_b.html

FDA OKs New Abbott HCV Test

SUMMARY

Abbott last week announced that the FDA approved a new PCR blood test for

hepatitis C virus (HCV) with a 12 IU/mL limit of detection and quantification.

Below is an edited excerpt from a recent Abbott press release describing the new

assay.

Abbott Receives FDA Approval for Molecular

Test for Hepatitis C

Abbott Park, Illinois -- May 18, 2011 -- Abbott (NYSE: ABT) announced today that

it has received approval from the U.S. Food and Drug Administration to market

its RealTime PCR (polymerase chain reaction) test for measuring the viral load

of hepatitis C (HCV), the leading cause of liver cancer in the United States.

The Abbott RealTime HCV assay, developed for use on the Abbott m2000 system, is

intended for use as an aid in the management of HCV-infected patients undergoing

antiviral therapy. The assay measures HCV RNA levels at baseline and during

treatment and can be utilized to predict sustained and non-sustained virological

response to HCV therapy. The results from the RealTime HCV assay must be

interpreted within the context of all relevant clinical and laboratory findings.

The Abbott RealTime HCV assay is not for screening blood, plasma, serum or

tissue donors for HCV, or to be used as a diagnostic test to confirm the

presence of HCV infection.

" With the addition of the HCV assay to its automated m2000 system, Abbott is the

only molecular diagnostics supplier in the U.S., to offer viral load assays for

HIV, HBV and HCV, and a combination test for chlamydia and gonorrhea, on a

single molecular platform, " said ph s, MD, associate medical director,

Abbott Molecular. " This enables laboratories to consolidate sexually transmitted

and infectious disease testing to improve workflow and productivity. Also,

having a single manufacturer of these tests provides the clinician with a level

of assurance of consistency and quality when managing patients. "

The Abbott RealTime HCV test offers precise measurement (quantitation) of HCV in

human plasma or serum. It is a highly sensitive HCV viral load test and the only

one for which the limit of detection (lowest level of virus that generates a

positive result) and the limit of quantitation (lowest exact viral load

measurement) are the same, 12 IU/mL. This level of sensitivity enables

clinicians to measure very low levels of the HCV virus to gauge success of

antiviral drug treatment for eradicating the infection.

" Monitoring HCV RNA levels is important in the management of the disease with

antiviral medications such as interferon and ribavirin, " said , MD, a

gastroenterologist and hepatitis researcher with the Schiff Liver Institute and

Center for Liver Diseases in Miami, and clinical investigator and consultant for

Abbott. " Viral load measurements help physicians determine whether to begin

antiviral therapy, influence decisions on dosing and therapy duration, and

identify drug resistant strains. "

" The Abbott RealTime HCV assay detects and measures the six most common HCV

genotypes by targeting an essential, highly conserved segment of the viral

genome, " said Stafford O', head of Abbott's molecular diagnostics business.

" It is a highly sensitive molecular assay and offers complete coverage of all

HCV genotypes, as demonstrated in peer reviewed publications. "

A study published in the June 2009 edition of the Journal of Clinical

Microbiology (Chevaliez, Bouvier-Alias, and Pawlotski) concluded that " the

Abbott m2000 RealTime PCR system for HCV RNA quantification is sensitive,

specific, and precise; that the results are reproducible; and that the

platform's broad dynamic range of quantification is well suited to HCV RNA

monitoring in the clinical setting. "

In addition to its HCV in vitro diagnostic products, Abbott currently has four

investigational pharmaceutical compounds in phase 2 clinical trials for the

treatment of HCV, including a protease inhibitor, two polymerase inhibitors and

an NS5A inhibitor.

About the Abbott m2000 System

Abbott's automated molecular diagnostics system, the m2000, utilizes real-time

polymerase chain reaction (PCR) technology for detecting and monitoring

infectious diseases and is designed to provide clinical laboratories a unique

system that fully automates all of the complex and heavily manual steps often

associated with molecular diagnostics.

Abbott currently markets the m2000 system and a menu of infectious disease

assays in countries throughout the world.

About Abbott Molecular

Abbott Molecular, abbottmolecular.com, is a leader in molecular diagnostics --

the analysis of DNA, RNA, and proteins at the molecular level. Abbott

Molecular's tests can also detect subtle but key changes in patients' genes and

chromosomes and have the potential for earlier detection or diagnosis, can

influence the selection of appropriate therapies, and may improve monitoring of

disease progression.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the

discovery, development, manufacture and marketing of pharmaceuticals and medical

products, including nutritionals, devices, and diagnostics. The company employs

nearly 90,000 people and markets its products in more than 130 countries.

5/24/11

Source

Abbott. Abbott Receives FDA Approval for Molecular Test for Hepatitis C. Press

release. May 18, 2011.